TY - JOUR
T1 - Short-Term and Long-Term Survival in Patients with Alcoholic Hepatitis Treated with Oxandrolone and Prednisolone
AU - The Veterans Administration Cooperative Study on Alcoholic Hepatitis
AU - Mendenhall, Charles L.
AU - Anderson, Sharon
AU - Garcia-Pont, Pedro
AU - Goldberg, Stephen
AU - Kiernan, Thomas
AU - Seeff, Leonard B.
AU - Sorrell, Michael
AU - Tamburro, Carlo
AU - Weesner, Robert
AU - Zetterman, Rowen
AU - Chedid, Antonio
AU - Chen, Thomas
AU - Rabin, Lionel
PY - 1984/12/6
Y1 - 1984/12/6
N2 - A cooperative study was conducted to determine the efficacy of 30 days of treatment with either a glucocorticosteroid (prednisolone) or an anabolic steroid (oxandrolone) in moderate or severe alcoholic hepatitis. One hundred thirty-two patients with moderate disease and 131 with severe disease were randomly assigned to one of three treatments: prednisolone, oxandrolone, or placebo. During the 30 days, mortality in the groups receiving steroid therapy was not significantly different from mortality in the placebo group. Thirteen percent of the moderately ill patients and 29 percent of the severely ill patients died. Although neither steroid improved short-term survival, oxandrolone therapy was associated with a beneficial effect on long-term survival. This was especially true in patients with moderate disease: among those who survived for one or two months after the start of treatment the conditional six-month death rate was 3.5 percent after oxandrolone and 19 to 20 percent after placebo (P = 0.02). No consistent long-term effect was associated with prednisolone therapy. (N Engl J Med 1984; 311:1464–70.).
AB - A cooperative study was conducted to determine the efficacy of 30 days of treatment with either a glucocorticosteroid (prednisolone) or an anabolic steroid (oxandrolone) in moderate or severe alcoholic hepatitis. One hundred thirty-two patients with moderate disease and 131 with severe disease were randomly assigned to one of three treatments: prednisolone, oxandrolone, or placebo. During the 30 days, mortality in the groups receiving steroid therapy was not significantly different from mortality in the placebo group. Thirteen percent of the moderately ill patients and 29 percent of the severely ill patients died. Although neither steroid improved short-term survival, oxandrolone therapy was associated with a beneficial effect on long-term survival. This was especially true in patients with moderate disease: among those who survived for one or two months after the start of treatment the conditional six-month death rate was 3.5 percent after oxandrolone and 19 to 20 percent after placebo (P = 0.02). No consistent long-term effect was associated with prednisolone therapy. (N Engl J Med 1984; 311:1464–70.).
UR - http://www.scopus.com/inward/record.url?scp=0021749036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021749036&partnerID=8YFLogxK
U2 - 10.1056/NEJM198412063112302
DO - 10.1056/NEJM198412063112302
M3 - Article
C2 - 6390194
AN - SCOPUS:0021749036
SN - 0028-4793
VL - 311
SP - 1464
EP - 1470
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 23
ER -